Filing Details
- Accession Number:
- 0001559515-20-000001
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-15 16:46:03
- Reporting Period:
- 2020-05-13
- Accepted Time:
- 2020-05-15 16:46:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1270073 | Intercept Pharmaceuticals Inc. | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1559515 | S.p.a. Genextra | Via G. De Grassi, 11 Milan L6 20123 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.001 Per Share | Disposition | 2020-05-13 | 595,578 | $84.60 | 5,500,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Genextra S.p.A. will apply the proceeds from the sale to reduce outstanding indebtedness under its margin loan secured by its shares of Intercept's common stock, and for general corporate purposes.
Billionaire Hedge Funds
